Should I buy or sell Ono Pharmaceutical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ono Pharmaceutical in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" OPHLY shares. View OPHLY analyst ratings or view top-rated stocks .

How have OPHLY shares performed in 2024?

Ono Pharmaceutical's stock was trading at $5.86 at the beginning of the year. Since then, OPHLY stock has decreased by 18.3% and is now trading at $4.79. View the best growth stocks for 2024 here .

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a decline in short interest in March. As of March 31st, there was short interest totaling 20,800 shares, a decline of 23.8% from the March 15th total of 27,300 shares. Based on an average daily trading volume, of 199,300 shares, the short-interest ratio is presently 0.1 days. View Ono Pharmaceutical's Short Interest .

Is Ono Pharmaceutical a good dividend stock?

Ono Pharmaceutical (OTCMKTS:OPHLY) pays an annual dividend of $16.56 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 362.62%. Payout ratios above 75% are not desirable because they may not be sustainable.

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:OPHLY

Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free OPHLY Stock Alerts

$4.79

-0.09 (-1.84%)

(As of 04/19/2024 ET)

Compare

Today's Range: $4.79
▼
$4.83
50-Day Range: $4.88
▼
$5.60
52-Week Range: $4.78
▼
$6.85

Volume: 208,874 shs
Average Volume: 98,306 shs
Market Capitalization: N/A

P/E Ratio: 1.05
Dividend Yield: 345.65%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Financials Headlines SEC Filings Short Interest

Get Ono Pharmaceutical alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Ono Pharmaceutical Stock (OTCMKTS:OPHLY)

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

OPHLY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPHLY Stock News Headlines

April 15, 2024 | americanbankingnews.com

Short Interest in Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Drops By 23.8%

March 6, 2024 | msn.com

Ono signs licence deal with NEX-I for cancer therapy

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

February 26, 2024 | finance.yahoo.com

Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results

February 19, 2024 | markets.businessinsider.com

InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery

February 15, 2024 | finance.yahoo.com

Ono Pharmaceutical Co., Ltd. (OPHLY)

February 14, 2024 | globenewswire.com

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer

February 10, 2024 | barrons.com

Ono Pharmaceutical Co. Ltd.

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

January 30, 2024 | markets.businessinsider.com

Ono Pharmaceutical earnings preview: what Wall Street is expecting

January 9, 2024 | finance.yahoo.com

Call for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed X

December 19, 2023 | finanznachrichten.de

The BioMed X Institute: BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research

November 28, 2023 | finance.yahoo.com

Nikkei Edges 0.2% Lower Amid JPY Strength

November 27, 2023 | finance.yahoo.com

China Shares Open Lower; Infrastructure Stocks Weigh

October 5, 2023 | msn.com

Ono Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Increased by 10.78% to 7.59

August 31, 2023 | finance.yahoo.com

Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases

August 31, 2023 | markets.businessinsider.com

Twist Bioscience To Develop Novel Antibodies With Ono Pharma

August 9, 2023 | finance.yahoo.com

Q2 2023 Fate Therapeutics Inc Earnings Call

August 3, 2023 | msn.com

Ono Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Decreased by 29.33% to 6.89

March 23, 2023 | technews.tmcnet.com

Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer

November 1, 2022 | benzinga.com

Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets

September 19, 2022 | finance.yahoo.com

3 Reasons Why Ono Pharmaceutical Co. (OPHLF) Is a Great Growth Stock

August 30, 2022 | seekingalpha.com

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

July 18, 2022 | benzinga.com

Ono Pharmaceutical (OTC:OPHLY), Earnings Estimates, EPS, and Revenue

July 18, 2022 | benzinga.com

Ono Pharmaceutical (OTC:OPHLY), Analyst Ratings, Price Targets, Predictions

July 7, 2022 | uk.finance.yahoo.com

Can Ono Pharmaceutical Co ride out the impact of economic shocks?

January 23, 2022 | nasdaq.com

Ono Pharmaceutical Co. Ltd ADR (OPHLY)

See More Headlines

Receive OPHLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Current Symbol: OTCMKTS:OPHLY
CUSIP: N/A
CIK: 940821
Web: www.ono.co.jp
Phone: (166) 263-5670
Fax: N/A
Employees: 3,761
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 1.05
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Gyo Sagara (Age 66)
CEO, President & Representative Director
Comp: $894.2k
Mr. Masaki Ito
Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax
Takehiro Yamada
Corporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion Office
Masayuki Tanigawa
Corporate Officer & Executive Director of Corporate Development & Strategy
Mr. Toichi Takino Ph.D. (Age 56)
Senior Managing Executive Officer, Head of Research Division & Director
Mr. Toshihiro Tsujinaka (Age 60)
Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director
Hiromu Habashita Ph.D.
Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of Immunology
Kiyoaki Idemitsu (Age 60)
Managing Executive Officer, GM of Development Division & Director
Shinji Takai M.D.
Ph.D., Corporate Officer & Head of Medical Affairs
Satoshi Takahagi
Corporate Officer and Executive Director of Sales, Marketing & Primary Care Business Division

Key Competitors

View All Competitors

OPHLY Stock Analysis - Frequently Asked Questions

Should I buy or sell Ono Pharmaceutical stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ono Pharmaceutical in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" OPHLY shares.
View OPHLY analyst ratings or view top-rated stocks.
How have OPHLY shares performed in 2024?: Ono Pharmaceutical's stock was trading at $5.86 at the beginning of the year. Since then, OPHLY stock has decreased by 18.3% and is now trading at $4.79.
View the best growth stocks for 2024 here.
Are investors shorting Ono Pharmaceutical?: Ono Pharmaceutical saw a decline in short interest in March. As of March 31st, there was short interest totaling 20,800 shares, a decline of 23.8% from the March 15th total of 27,300 shares. Based on an average daily trading volume, of 199,300 shares, the short-interest ratio is presently 0.1 days.
View Ono Pharmaceutical's Short Interest.

Is Ono Pharmaceutical a good dividend stock?: Ono Pharmaceutical (OTCMKTS:OPHLY) pays an annual dividend of $16.56 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 362.62%. Payout ratios above 75% are not desirable because they may not be sustainable.
How do I buy shares of Ono Pharmaceutical?: Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OPHLY) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial